Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.64 |
| ▸ | ABCG2 | Q9UNQ0 | 9/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.51 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2154779 | 0.81 | KMT2A (0.43) | PDE5AABCG2RAB9AKMT2AOPRK1 | |
| SCHEMBL2154602 | 0.80 | PDE5A (0.62) | PDE5AABCG2RAB9AKMT2AMAPT | |
| SCHEMBL14726166 | 0.80 | PDE5A (0.50) | PDE5AKMT2AMAPTALDH1A1MEN1 | |
| SCHEMBL14726136 | 0.80 | ABCG2 (0.72) | PDE5AABCG2 | |
| Hydrochloric Acid SCHEMBL7280013 | 0.79 | PDE5A (0.63) | PDE5AABCG2RAB9AKMT2AMAPT | |
| SCHEMBL31399886 | 0.79 | KMT2A (0.53) | ABCG2RAB9AKMT2AOPRK1MAPT | |
| SCHEMBL16183305 | 0.78 | GBA1 (0.49) | PDE5AKMT2AMAPTALDH1A1MEN1 | |
| SCHEMBL15966763 | 0.78 | CYP3A4 (0.57) | PDE5AKMT2AMAPTALDH1A1MEN1 | |
| SCHEMBL7287561 | 0.78 | PDE5A (1.00) | PDE5AABCG2KMT2AMAPTALDH1A1 | |
| SCHEMBL14726233 | 0.78 | PDE5A (0.60) | PDE5ARAB9AKMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | OSI PHARMACEUTICALS, INC. | 2002-02-28 | — | — | US | disclosed |
| EP-0579496-B1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO (JP) | 2001-11-14 | — | — | EP | disclosed |
| US-5439895-A | Cardiovascular disorders; inhibitor of thromboxane A2 synthetase and cyclic guanosine 3',5'-monophosphate | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
| US-5436233-A | Nervous system disorders | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| EP-0579496-A1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | VHL, MCL1, NFATC1 | PDE5A 3794/4885ABCG2 3440/4885RAB9A 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.